A proposed protocol for monitoring ototoxicity in patients who take cochleo- or vestibulotoxic drugs

Ear, Nose and Throat Journal

Volumn 82, Issue 3, 2003, Pages 181-184

  Vasquez, Rachel ^a   Mattucci, Kenneth F ^a  

^a N Shore Otolaryngology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARSENIC; CARBOPLATIN; CHLORAMPHENICOL; CHLORMETHINE; CHLOROQUINE; CISPLATIN; CLINDAMYCIN; COCAINE; DEFEROXAMINE; ERYTHROMYCIN; ETHAMBUTOL; FLUOROURACIL; GOLD; ISONIAZID; LEAD; LINCOMYCIN; LOOP DIURETIC AGENT; METHOTREXATE; ORGANIC SOLVENT; POLYMYXIN B; PROCARBAZINE; STYRENE; UNINDEXED DRUG; VANCOMYCIN; VIOMYCIN;

ARTICLE; CLINICAL PROTOCOL; COCHLEA; HUMAN; MONITORING; OTOTOXICITY; RISK FACTOR; VESTIBULAR SYSTEM;

EID: 0037343902     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130308200310     Document Type: Article

References (11)

1. Quick CA. Chemical and drug effects on the inner ear. In: Paparella MM, Schumrick DA, eds. Otolaryngology. Vol. 2. Philadelphia: W.B. Saunders, 1973:391-405.
2. Leonard G, Owen-Black F, Schramm V. Diseases of the inner ear and sensorineural deafness. In: Bluestone CD, Stool SE, eds. Pediatric Otolaryngology. Philadelphia: W.B. Saunders, 1983:271-7.
3. Jackler RK, Brackmann DE. Neurotology. St. Louis: Mosby, 1994:621-44.
4. Rybak LP, Kanno H. Ototoxicity. In: Ballenger JJ, Snow JB, Jr., eds. Otorhinolaryngology-Head and Neck Surgery. 15th ed. Baltimore: Williams and Wilkins, 1996:1102-7.
5. Rybak LP, ed. Ototoxicity. Otolaryngologic Clinics of North America. Vol. 26. Philadelphia: W.B. Saunders, 1993.
6. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;36(Suppl 12):11-9.
7. Campbell KC, Durrant J. Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am 1993;26:903-14.
8. Meyerhoff WL, ed. Diagnosis and Management of Hearing Loss. Philadelphia: W.B. Saunders, 1984:74-5.
9. Finley RS, Fortner CL, deJongh CA, et al. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother 1982;22:193-7.
10. Lerner SA, Schmitt BA, Seligsohn CA, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986;80(Suppl 6B):98-104.
11. Baloh RW, Honrubia V. Clinical Neurophysiology of the Vestibular System. Philadelphia: F.A. Davis, 1990:259-62.